Terms: = Breast cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
2680 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
[TBL] [Abstract] [Full Text] [Related]
3. A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy.
Ascheid D; Baumann M; Pinnecker J; Friedrich M; Szi-Marton D; Medved C; Bundalo M; Ortmann V; Öztürk A; Nandigama R; Hemmen K; Ergün S; Zernecke A; Hirth M; Heinze KG; Henke E
Nat Commun; 2024 Apr; 15(1):3599. PubMed ID: 38678014
[TBL] [Abstract] [Full Text] [Related]
4. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
5. Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT project.
Potter S; Avery K; Ahmed R; de Boniface J; Chatterjee S; Dodwell D; Dubsky P; Iwata H; Jiang M; Lee HB; MacKenzie M; Poulakaki F; Richardson AL; Sepulveda K; Spillane A; Thompson AM; Werutsky G; Wright JL; Zdenkowski N; Cowan K; McIntosh S
BMJ Open; 2024 Apr; 14(4):e084488. PubMed ID: 38643011
[TBL] [Abstract] [Full Text] [Related]
6. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract] [Full Text] [Related]
7. BRCA2 Polymorphisms and breast cancer Susceptibility: a Multi-Tools Bioinformatics Approach.
Jan H; Khan NU; Al-Qaaneh AM; Tasleem M; Almutairi MH; Ali I
Cell Physiol Biochem; 2024 Mar; 58(2):128-143. PubMed ID: 38623065
[TBL] [Abstract] [Full Text] [Related]
8. Differentiation of invasive ductal and lobular carcinoma of the breast using MRI radiomic features: a pilot study.
Maiti S; Nayak S; Hebbar KD; Pendem S
F1000Res; 2024; 13():91. PubMed ID: 38571894
[TBL] [Abstract] [Full Text] [Related]
9. Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study.
Zhu K; Sui Y; Zhu M; Gao Y; Yuan Y; Sun P; Meng L; Dai J; Li Z
PLoS One; 2024; 19(4):e0301057. PubMed ID: 38557552
[TBL] [Abstract] [Full Text] [Related]
10. Wireless electrostimulation for cancer treatment: An integrated nanoparticle/coaxial fiber mesh platform.
Resina L; Garrudo FFF; Alemán C; Esteves T; Ferreira FC
Biomater Adv; 2024 Jun; 160():213830. PubMed ID: 38552500
[TBL] [Abstract] [Full Text] [Related]
11. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
12. [Not Available].
Maraldo MV; Offersen BV
Ugeskr Laeger; 2024 Mar; 186(12):. PubMed ID: 38533873
[TBL] [Abstract] [Full Text] [Related]
13. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract] [Full Text] [Related]
14. Cycloplatinated (II) Complex Based on Isoquinoline Alkaloid Elicits Ferritinophagy-Dependent Ferroptosis in Triple-Negative breast cancer Cells.
Wang FY; Yang LM; Wang SS; Lu H; Wang XS; Lu Y; Ni WX; Liang H; Huang KB
J Med Chem; 2024 Apr; 67(8):6738-6748. PubMed ID: 38526421
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract] [Full Text] [Related]
16. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-cancer Clinicogenomic Data set.
Kehl KL; Lavery JA; Brown S; Fuchs H; Riely G; Schrag D; Newcomb A; Nichols C; Micheel CM; Bedard PL; Sweeney SM; Fiandalo M; Panageas KS;
JCO Precis Oncol; 2024 Mar; 8():e2300489. PubMed ID: 38484212
[TBL] [Abstract] [Full Text] [Related]
17. Postabsorptive and postprandial glucose and fat metabolism in postmenopausal women with breast cancer-Preliminary data after chemotherapy compared to healthy controls.
Buch-Larsen K; Gillberg L; Ahmed HI; Marstrand SD; Andersson M; van Hall G; Brøns C; Schwarz P
Nutrition; 2024 Jun; 122():112394. PubMed ID: 38458062
[TBL] [Abstract] [Full Text] [Related]
18. Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
Goh SP; Ong SC; Chan JE
BMC Cancer; 2024 Mar; 24(1):316. PubMed ID: 38454347
[TBL] [Abstract] [Full Text] [Related]
19. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on cancer Reporting (ICCR).
Bossuyt V; Provenzano E; Symmans WF; Webster F; Allison KH; Dang C; Gobbi H; Kulka J; Lakhani SR; Moriya T; Quinn CM; Sapino A; Schnitt S; Sibbering DM; Slodkowska E; Yang W; Tan PH; Ellis I
Histopathology; 2024 Jun; 84(7):1111-1129. PubMed ID: 38443320
[TBL] [Abstract] [Full Text] [Related]
20. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract] [Full Text] [Related]
[Next]
